24623-39-0

Basic information

• Product Name: 1,3-Dichloro-6-methoxyisoquinoline
• Synonyms: 1,3-Dichloro-6-methoxyisoquinoline;1,3-Dichloro-6-methoxyisoquinoline 98%;3-dichloro-6-Methoxyisoquinoline;1,3-Dichloro-6-methoxyisoquinoline98%
• CAS NO: 24623-39-0
• Molecular Formula: C₁₀H₇Cl₂NO
• Molecular Weight: 228.07468
• Product Categories: blocks;Heterocycles;Quinolines;Quinoline&Isoquinoline
• Mol File: 24623-39-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 367.203 °C at 760 mmHg
• Flash Point: 175.878 °C
• Appearance: /
• Density: 1.385g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,3-Dichloro-6-methoxyisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dichloro-6-methoxyisoquinoline(24623-39-0)
• EPA Substance Registry System: 1,3-Dichloro-6-methoxyisoquinoline(24623-39-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 24623-39-0(Hazardous Substances Data)

Usage

General Description

1,3-Dichloro-6-methoxyisoquinoline is a chemical compound with the molecular formula C11H8Cl2NO. It is an isoquinoline derivative with two chlorine atoms and a methoxy group attached to the carbon atoms in the 1 and 6 positions, respectively. 1,3-Dichloro-6-methoxyisoquinoline is often used in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and potential biological activities. It is also a valuable building block in organic chemistry for the preparation of complex molecules. Additionally, it has been studied for its potential use in the treatment of cancer and other diseases, as well as its antimicrobial and antifungal properties. However, it is important to handle this compound with caution due to its potential hazardous properties.

InChI:InChI=1/C10H7Cl2NO/c1-14-7-2-3-8-6(4-7)5-9(11)13-10(8)12/h2-5H,1H3

Upstream product

• 630422-24-1 1-chloro-6-methoxy-isoquinoline 2-oxide 

Relevant articles and documents

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein X is N, CH and where X bears a double bond it is C; R1 is -OR5, -NH-SO2R6; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; R4 is isoquinolinyl optionally substituted with one, two or three substituents each independently selected from C1-6alkyl, C1-6alkoxy, hydroxy, halo, polyhalo- C1-6alkyl, polyhaloC1-6alkoxy, amino, mono- or diC1-6alkylamino, mono- or DiC1-6alkylaminocarbonyl, C1-6alkylcarbonyl-amino, aryl, and Het; n is 3, 4, 5, or 6; each dashed line (represented by ) represents an optional double bond; R5 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R6 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; each aryl is phenyl optionally substituted with one, two or three substituents; and each Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.